Suppr超能文献

深静脉血栓再通的分析:华法林与利伐沙班治疗患者的对比研究

Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban.

作者信息

Piati Polyana Klomfass, Peres Aline Krampe, de Andrade Danielle Oliveira, Jorge Mirela Andressa, Toregeani Jeferson Freitas

机构信息

Faculdade Assis Gurgacz - FAG, Cascavel, PR, Brasil.

出版信息

J Vasc Bras. 2019 Jun 17;18:e20180111. doi: 10.1590/1677-5449.180111.

Abstract

BACKGROUND

Deep venous thrombosis (DVT) strikes around ten million people worldwide every year and is associated with major complications including pulmonary embolism and post-thrombotic syndrome. Anticoagulation is the standard treatment, with administration of heparins, vitamin K antagonists, fondaparinux, or, more recently, direct oral anticoagulants (DOACs). Anticoagulants reduce thrombus progression and facilitate natural thrombolytic mechanisms, leading to a phenomenon known as recanalization, which can occur in varying degrees and over variable periods of time, under influence from many different factors, including the type of anticoagulation employed.

OBJECTIVES

To evaluate the degree of recanalization and the time taken, by analysis of color Doppler ultrasonography (CDU) reports from patients with DVT treated with DOACs or with heparin + warfarin.

METHODS

A retrospective analysis was conducted of demographic data and CDU reports from patients with DVT who had been treated from January 2009 to December 2016. These patients were classified into two groups, according to the treatment given: Group I (heparin + warfarin): 26 patients; or Group II (rivaroxaban): 51 patients. The primary outcomes assessed were degree of recanalization and time taken.

RESULTS

Recanalization rates at 30, 90, and 180 days were 10%, 52.5%, and 78.9%, respectively, in Group I, and 55.3%, 83.5%, and 92.4%, respectively, in Group II, with statistically significant difference (p = 0.041).

CONCLUSIONS

Both treatments led to recanalization. Recanalization occurred earlier among patients treated with rivaroxaban.

摘要

背景

每年全球约有1000万人发生深静脉血栓形成(DVT),其与包括肺栓塞和血栓形成后综合征在内的主要并发症相关。抗凝是标准治疗方法,可使用肝素、维生素K拮抗剂、磺达肝癸钠,或者最近使用的直接口服抗凝剂(DOACs)。抗凝剂可减少血栓进展并促进自然溶栓机制,从而导致一种称为再通的现象,在包括所用抗凝类型在内的许多不同因素影响下,再通可在不同程度和不同时间段内发生。

目的

通过分析接受DOACs或肝素+华法林治疗的DVT患者的彩色多普勒超声(CDU)报告,评估再通程度和所需时间。

方法

对2009年1月至2016年12月接受治疗的DVT患者的人口统计学数据和CDU报告进行回顾性分析。根据所给予的治疗方法,将这些患者分为两组:第一组(肝素+华法林):26例患者;第二组(利伐沙班):51例患者。评估的主要结局为再通程度和所需时间。

结果

第一组在30、90和180天时的再通率分别为10%、52.5%和78.9%,第二组分别为55.3%、83.5%和92.4%,差异有统计学意义(p = 0.041)。

结论

两种治疗均导致再通。接受利伐沙班治疗的患者再通发生得更早。

相似文献

3
Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome.
Int Angiol. 2019 Feb;38(1):17-21. doi: 10.23736/S0392-9590.18.04031-2. Epub 2018 Nov 20.
4
A retrospective assessment of venous recanalization outcomes for oral anticoagulant treatment in deep vein thrombosis.
Vascular. 2025 Feb;33(1):143-150. doi: 10.1177/17085381241236931. Epub 2024 Feb 26.
6
Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome.
Thromb Res. 2017 Sep;157:46-48. doi: 10.1016/j.thromres.2017.05.029. Epub 2017 May 29.
7
Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin.
J Thromb Thrombolysis. 2020 Feb;49(2):199-205. doi: 10.1007/s11239-019-01932-8.
8
Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
Vascul Pharmacol. 2020 Jan;124:106608. doi: 10.1016/j.vph.2019.106608. Epub 2019 Oct 31.
9
Direct oral anticoagulant agents might be safe for patients undergoing endovenous radiofrequency and laser ablation.
J Vasc Surg Venous Lymphat Disord. 2023 Jan;11(1):25-30. doi: 10.1016/j.jvsv.2022.05.011. Epub 2022 Jul 21.
10
Factors Affecting Recanalization in Femoropopliteal Deep Vein Thrombosis.
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231173409. doi: 10.1177/10760296231173409.

引用本文的文献

1
Anticoagulation Management Post Pulmonary Embolism.
Methodist Debakey Cardiovasc J. 2024 May 16;20(3):27-35. doi: 10.14797/mdcvj.1338. eCollection 2024.
2
Body Iron Store and its Association with Risk of First Episode of Spontaneous Lower Extremity Deep Vein Thrombosis/ Pulmonary Embolism: A Case-Control Study.
Indian J Hematol Blood Transfus. 2023 Jul;39(3):442-449. doi: 10.1007/s12288-022-01606-1. Epub 2022 Nov 10.
3
Predictive factors of venous recanalization in upper-extremity vein thrombosis.
PLoS One. 2021 May 13;16(5):e0251269. doi: 10.1371/journal.pone.0251269. eCollection 2021.

本文引用的文献

1
Direct oral anticoagulants for treatment of deep vein thrombosis: overview of systematic reviews.
J Vasc Bras. 2018 Oct-Dec;17(4):310-317. doi: 10.1590/1677-5449.005518.
2
New anticoagulants for the treatment of venous thromboembolism.
J Bras Pneumol. 2016 Apr;42(2):146-54. doi: 10.1590/S1806-37562016042020068.
3
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.
4
Guidance for the prevention and treatment of the post-thrombotic syndrome.
J Thromb Thrombolysis. 2016 Jan;41(1):144-53. doi: 10.1007/s11239-015-1312-5.
5
Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: scope of the problem.
Ther Adv Drug Saf. 2015 Apr;6(2):57-66. doi: 10.1177/2042098615572333.
6
Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment.
Thromb J. 2015 Mar 14;13:13. doi: 10.1186/s12959-015-0045-1. eCollection 2015.
7
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program.
Thromb J. 2015 Jan 17;13:2. doi: 10.1186/s12959-015-0035-3. eCollection 2015.
9
Thrombosis: a major contributor to the global disease burden.
J Thromb Haemost. 2014 Oct;12(10):1580-90. doi: 10.1111/jth.12698.
10
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283. Epub 2014 Aug 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验